pharmaphorum

JANUARY 21, 2022

Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution that works for everyone. Balancing the incentivisation of innovation against affordable access to revolutionary new medicines is an age-old conundrum in the biopharmaceutical industry.

Insurance 52

Insurance Vaccines 52

pharmaphorum

JUNE 2, 2021

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. “NICE’s initial ‘no’ to approving risdiplam for NHS funding is not unexpected,” said SMA UK this morning.

Documentation 52

Documentation Communication 52

pharmaphorum

AUGUST 28, 2020

Prof Brownstein, who is also chief innovation officer at Boston Children’s Hospital, said: “COVID-19 has put a real focus on the inadequacies of public health. Established with funding from the National Library of Medicine (NLM), it pulls data from sources including news stories, blogs, social media, and chat rooms. “We

Hospitals 71

Hospitals 71

European Pharmaceutical Review

JULY 11, 2022

Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . Manufacturing efforts for the project will be led by the UK’s Centre for Process Innovation ( CPI ) using microbes engineered by biotechnology Ingenza Ltd. The innovative protein ?“glue”

Vaccines 94

Vaccines Immunization 94